NFSG
BCRX icon

Newbridge Financial Services Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Newbridge Financial Services Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15
Closed -$76 – 1099
2024
Q1 		$76 Buy
+15
New +$84 ﹤0.01% 1147

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Newbridge Financial Services Group's BCRX Position: Q2 2024 in Review

Newbridge Financial Services Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 15 shares — an estimated $76 sold.

Newbridge Financial Services Group first reported a position in BCRX in Q1 2024 and held it in 1 quarter. The position peaked at $76 in Q1 2024. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Newbridge Financial Services Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 15 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $76.
  • Newbridge Financial Services Group first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Newbridge Financial Services Group's BioCryst Pharmaceuticals position peaked at $76 in Q1 2024.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Newbridge Financial Services Group's 13F filing for Q2 2024, filed 11 Sep 2024.